Core Insights - Jiangsu Aipeng Medical Technology Co., Ltd. conducted a conference call with 13 institutions, including Cinda Securities and Southern Fund, to discuss its business and future strategies [1] Company Overview - Aipeng Medical focuses on medical devices, particularly in chronic pain management and upper airway management, while also expanding into brain-computer interface (BCI) innovations [1] - The company's BCI applications include perioperative brain state monitoring, treatment systems for refractory insomnia, and multi-modal ADHD behavior management systems [1] Product Development - In the non-invasive sector, Aipeng has developed a multi-modal ADHD behavior management system that connects data from hospital to home, utilizing scientific EEG monitoring and multi-modal interventions [2] - The company has launched an anesthesia treatment system for refractory insomnia and is in the preliminary research phase for an epilepsy warning platform [2] - Aipeng has established a partnership with Changzhou Ruishen'an, focusing on the development and production of neuro-regulation and intracranial electrode medical devices [2] Market Expansion - Hospitals in provinces such as Hubei, Zhejiang, and Guangdong have announced pricing for BCI medical services, facilitating clinical application [2] - The new generation ADM series anesthesia depth monitoring device has received three registration certificates and is now available for sale in over 20 provinces [2] - The refractory insomnia anesthesia treatment system has been implemented in hospitals for clinical treatment and promotion [2] Consumer Product Strategy - The refractory insomnia anesthesia treatment system and multi-modal ADHD behavior management system target both hospital and consumer markets [2] - The multi-modal ADHD behavior training products include UMind (hospital version) and SE (home version), initially promoted in serious medical settings before expanding to consumer markets [2] Data Infrastructure - The refractory insomnia anesthesia treatment system is designed to meet clinical needs, incorporating smart interaction between doctors and patients, and tracking clinical data [2] - The multi-modal ADHD behavior training system integrates multi-source data collection and analysis, collaborating with Fudan University Children's Hospital to enhance data infrastructure and clinical application [2] Research and Development - Aipeng is building a BCI technology application platform to advance clinical innovations in mental health diagnosis and treatment [2] - The company aims to enhance its R&D capabilities and strengthen collaborations with renowned universities and research institutions to promote technological innovation and industry integration [2]

Core Viewpoint - The company has launched its next-generation ADM series anesthesia depth monitoring products, although revenue from these products is currently small [1] Group 1: Product Development - The multi-modal ADHD behavioral training system has recently obtained two medical device registration certificates and production licenses, but has not yet generated revenue [1] - The company’s subsidiary, Changzhou Ruishen'an, has received registration certificates for implanted deep brain stimulators (CNS) and implanted drug delivery devices (IDDS) [1] Group 2: Strategic Partnerships - The company has signed a partnership with the Children's Hospital affiliated with Fudan University to establish a joint laboratory [1] - The company has made a strategic investment in a specialized service organization focused on ADHD behavioral training, named Fangcun Doctor, to deepen collaboration [1] Group 3: Future Directions - The company will continue to advance clinical applications in perioperative brain state monitoring, sleep disease diagnosis, ADHD, epilepsy, and other mental health disorders [1] - The company has established an Artificial Intelligence and Brain-Machine Engineering Research Institute to explore more possibilities at the intersection of brain-machine interface technology and clinical applications [1]

Core Viewpoint - The company has launched its new generation ADM series anesthesia depth monitoring products, although the revenue scale is currently small [1] Product Development - The multimodal ADHD behavioral training system has recently obtained two medical device registration certificates and production licenses, but has not yet generated revenue [1] - The external layout of Changzhou Ruishen'an has recently received registration certificates for implanted deep brain stimulators (CNS) and implanted drug delivery devices (IDDS) [1] Strategic Partnerships - The company has signed a partnership with the Children's Hospital affiliated with Fudan University to establish a joint laboratory [1] - The company has strategically invested in a specialized service organization focused on ADHD behavioral training therapy, known as Fangcun Doctor, to conduct in-depth cooperation [1] Research and Development Focus - The company will continue to advance clinical applications in perioperative brain state monitoring, diagnosis of sleep disorders, ADHD, epilepsy, and other mental health conditions [1] - The establishment of an Artificial Intelligence and Brain-Machine Engineering Research Institute aims to explore more possibilities at the intersection of brain-machine interface technology and clinical applications, driven by cutting-edge technology [1]

Core Insights - The brain-computer interface (BCI) industry is experiencing rapid growth and innovation, marking it as a significant area for technological and industrial integration [1][7] - The A-share market has shown strong performance, with the Shanghai Composite Index reaching a nearly 10-year high, indicating robust investor interest [1][2] Industry Developments - The first global multi-center clinical trial for a neural critical care brain-computer interface has been launched, focusing on precise diagnosis and treatment of hydrocephalus [5] - The project aims to expand BCI applications beyond traditional motor and cognitive function recovery, paving the way for new medical applications [5][6] - A comprehensive "end-edge-cloud" BCI intelligent platform has been developed, significantly reducing the diagnosis time for hydrocephalus from 2-3 days to 30 minutes [6] Market Trends - The Chinese BCI market is projected to grow from 3.2 billion yuan in 2024 to 6.14 billion yuan by 2028, reflecting increasing demand driven by aging populations and industrial upgrades [7] - Over 30 listed companies are currently involved in the BCI industry, with significant product launches and innovations reported [8][10] Stock Performance - BCI concept stocks have seen an average increase of 47.88% this year, outperforming the Shanghai Composite Index, with six stocks rising over 80% [10] - Notable companies in the sector include Xiangyu Medical, Hanwei Technology, and Aipeng Medical, which have introduced various BCI products [10][9] Investment Activity - As of August 22, seven BCI concept stocks have recorded net financing purchases exceeding 100 million yuan in August, indicating strong investor interest [13]